Logo image of PACS

PACS GROUP INC (PACS) Stock Fundamental Analysis

NYSE:PACS - New York Stock Exchange, Inc. - US69380Q1076 - Common Stock - Currency: USD

10.14  -0.4 (-3.8%)

Fundamental Rating

3

Overall PACS gets a fundamental rating of 3 out of 10. We evaluated PACS against 102 industry peers in the Health Care Providers & Services industry. Both the profitability and financial health of PACS have multiple concerns. PACS has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

PACS had positive earnings in the past year.
PACS Yearly Net Income VS EBIT VS OCF VS FCFPACS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 50M -50M 100M 150M 200M

1.2 Ratios

With a decent Return On Assets value of 2.90%, PACS is doing good in the industry, outperforming 62.75% of the companies in the same industry.
The Return On Equity of PACS (19.73%) is better than 87.25% of its industry peers.
PACS has a Return On Invested Capital (4.38%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA 2.9%
ROE 19.73%
ROIC 4.38%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PACS Yearly ROA, ROE, ROICPACS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 50 100 150 200

1.3 Margins

PACS's Profit Margin of 3.63% is fine compared to the rest of the industry. PACS outperforms 70.59% of its industry peers.
PACS has a Operating Margin of 6.68%. This is in the better half of the industry: PACS outperforms 70.59% of its industry peers.
PACS has a Gross Margin (21.33%) which is in line with its industry peers.
Industry RankSector Rank
OM 6.68%
PM (TTM) 3.63%
GM 21.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PACS Yearly Profit, Operating, Gross MarginsPACS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 5 10 15 20

More info and screens

2

2. Health

2.1 Basic Checks

PACS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, PACS has about the same amount of shares outstanding.
The debt/assets ratio for PACS is higher compared to a year ago.
PACS Yearly Shares OutstandingPACS Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 50M 100M
PACS Yearly Total Debt VS Total AssetsPACS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 1B 2B 3B

2.2 Solvency

PACS has an Altman-Z score of 1.41. This is a bad value and indicates that PACS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PACS (1.41) is worse than 63.73% of its industry peers.
PACS has a Debt/Equity ratio of 0.90. This is a neutral value indicating PACS is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.90, PACS is not doing good in the industry: 62.75% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Altman-Z 1.41
ROIC/WACC0.53
WACC8.23%
PACS Yearly LT Debt VS Equity VS FCFPACS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 200M 400M 600M

2.3 Liquidity

PACS has a Current Ratio of 1.71. This is a normal value and indicates that PACS is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of PACS (1.71) is comparable to the rest of the industry.
A Quick Ratio of 1.71 indicates that PACS should not have too much problems paying its short term obligations.
PACS has a better Quick ratio (1.71) than 64.71% of its industry peers.
Industry RankSector Rank
Current Ratio 1.71
Quick Ratio 1.71
PACS Yearly Current Assets VS Current LiabilitesPACS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

PACS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -25.00%.
PACS shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.47%.
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-144.3%
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.08%

3.2 Future

PACS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.81% yearly.
The Revenue is expected to grow by 18.88% on average over the next years. This is quite good.
EPS Next Y92.3%
EPS Next 2Y56.05%
EPS Next 3Y40.81%
EPS Next 5YN/A
Revenue Next Year29.74%
Revenue Next 2Y21.73%
Revenue Next 3Y18.88%
Revenue Next 5YN/A

3.3 Evolution

PACS Yearly Revenue VS EstimatesPACS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 1B 2B 3B 4B 5B
PACS Yearly EPS VS EstimatesPACS Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 0.5 1 1.5 2

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 13.34 indicates a correct valuation of PACS.
PACS's Price/Earnings ratio is rather cheap when compared to the industry. PACS is cheaper than 81.37% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.60, PACS is valued a bit cheaper.
With a Price/Forward Earnings ratio of 5.45, the valuation of PACS can be described as very cheap.
Based on the Price/Forward Earnings ratio, PACS is valued cheaper than 97.06% of the companies in the same industry.
PACS's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.43.
Industry RankSector Rank
PE 13.34
Fwd PE 5.45
PACS Price Earnings VS Forward Price EarningsPACS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PACS indicates a somewhat cheap valuation: PACS is cheaper than 76.47% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 8.97
PACS Per share dataPACS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15 20

4.3 Compensation for Growth

PACS's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PACS's earnings are expected to grow with 40.81% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.14
PEG (5Y)N/A
EPS Next 2Y56.05%
EPS Next 3Y40.81%

More info and screens

0

5. Dividend

5.1 Amount

PACS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PACS GROUP INC

NYSE:PACS (5/21/2025, 12:38:44 PM)

10.14

-0.4 (-3.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)N/A N/A
Inst Owners32.33%
Inst Owner Change-6.29%
Ins Owners72.29%
Ins Owner Change-0.49%
Market Cap1.57B
Analysts83.64
Price Target36.31 (258.09%)
Short Float %6.27%
Short Ratio5.26
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.28%
Min EPS beat(2)24.18%
Max EPS beat(2)56.37%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)3.83%
Min Revenue beat(2)2.62%
Max Revenue beat(2)5.03%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.78%
PT rev (3m)9.78%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1.25%
EPS NY rev (1m)0%
EPS NY rev (3m)23.43%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.89%
Revenue NY rev (1m)-0.49%
Revenue NY rev (3m)-0.47%
Valuation
Industry RankSector Rank
PE 13.34
Fwd PE 5.45
P/S 0.51
P/FCF N/A
P/OCF N/A
P/B 2.75
P/tB 3.1
EV/EBITDA 8.97
EPS(TTM)0.76
EY7.5%
EPS(NY)1.86
Fwd EY18.34%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS20.05
BVpS3.69
TBVpS3.27
PEG (NY)0.14
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.9%
ROE 19.73%
ROCE 6.06%
ROIC 4.38%
ROICexc 4.47%
ROICexgc 4.56%
OM 6.68%
PM (TTM) 3.63%
GM 21.33%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.8
Health
Industry RankSector Rank
Debt/Equity 0.9
Debt/FCF N/A
Debt/EBITDA 2.21
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.71
Quick Ratio 1.71
Altman-Z 1.41
F-ScoreN/A
WACC8.23%
ROIC/WACC0.53
Cap/Depr(3y)671.95%
Cap/Depr(5y)N/A
Cap/Sales(3y)4.35%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-144.3%
EPS Next Y92.3%
EPS Next 2Y56.05%
EPS Next 3Y40.81%
EPS Next 5YN/A
Revenue 1Y (TTM)28.47%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%29.08%
Revenue Next Year29.74%
Revenue Next 2Y21.73%
Revenue Next 3Y18.88%
Revenue Next 5YN/A
EBIT growth 1Y-9.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year86.39%
EBIT Next 3Y38.06%
EBIT Next 5YN/A
FCF growth 1Y-74.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.22%
OCF growth 3YN/A
OCF growth 5YN/A